[go: up one dir, main page]

EA201270752A1 - Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью - Google Patents

Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью

Info

Publication number
EA201270752A1
EA201270752A1 EA201270752A EA201270752A EA201270752A1 EA 201270752 A1 EA201270752 A1 EA 201270752A1 EA 201270752 A EA201270752 A EA 201270752A EA 201270752 A EA201270752 A EA 201270752A EA 201270752 A1 EA201270752 A1 EA 201270752A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinase inhibitors
malignant tumor
help
treating malignant
structural formula
Prior art date
Application number
EA201270752A
Other languages
English (en)
Other versions
EA023173B1 (ru
Inventor
Питер Брент Сампсон
Юн Лю
Сцзе-Вань Ли
Брайан Т. Форрест
Хайнц В. Паулс
Луис Г. Эдвардс
Миклос Фехер
Нарендра Кумар Б. Пател
Радослав Лауфер
Гуохуа Пан
Original Assignee
Юниверсити Хелс Нетворк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2010/000518 external-priority patent/WO2010115279A1/en
Application filed by Юниверсити Хелс Нетворк filed Critical Юниверсити Хелс Нетворк
Publication of EA201270752A1 publication Critical patent/EA201270752A1/ru
Publication of EA023173B1 publication Critical patent/EA023173B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Изобретение относится к соединению, представленному следующей структурной формулой, и его фармацевтически приемлемым солям:Представленные этой структурной формулой соединения представляют собой ингибиторы киназы, и они, следовательно, раскрыты в настоящем документе для лечения злокачественной опухоли. Определения переменных в структурной формуле приведены в настоящем описании.
EA201270752A 2010-04-06 2011-04-06 Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью EA023173B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32132910P 2010-04-06 2010-04-06
US32133210P 2010-04-06 2010-04-06
PCT/CA2010/000518 WO2010115279A1 (en) 2009-04-06 2010-04-06 Kinase inhibitors and method of treating cancer with same
PCT/CA2011/000386 WO2011123946A1 (en) 2010-04-06 2011-04-06 Kinase inhibitors and method of treating cancer with same

Publications (2)

Publication Number Publication Date
EA201270752A1 true EA201270752A1 (ru) 2013-04-30
EA023173B1 EA023173B1 (ru) 2016-04-29

Family

ID=44761967

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270752A EA023173B1 (ru) 2010-04-06 2011-04-06 Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью

Country Status (25)

Country Link
US (9) US8921545B2 (ru)
EP (2) EP2556071B1 (ru)
JP (1) JP5442906B2 (ru)
KR (1) KR101782668B1 (ru)
CN (1) CN102892766B (ru)
AU (1) AU2011238384B2 (ru)
BR (1) BR112012025496B1 (ru)
CY (1) CY1118610T1 (ru)
DK (1) DK2556071T3 (ru)
EA (1) EA023173B1 (ru)
ES (2) ES2603613T3 (ru)
HR (1) HRP20161498T1 (ru)
HU (1) HUE030651T2 (ru)
IL (1) IL221556A (ru)
LT (1) LT2556071T (ru)
ME (1) ME02545B (ru)
MX (1) MX2012011516A (ru)
NZ (1) NZ602350A (ru)
PL (1) PL2556071T3 (ru)
PT (1) PT2556071T (ru)
SG (1) SG183875A1 (ru)
SI (1) SI2556071T1 (ru)
SM (1) SMT201600430B (ru)
TW (1) TWI516262B (ru)
WO (2) WO2011123947A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2235004A4 (en) * 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
ME02545B (me) 2010-04-06 2017-02-20 Univ Health Network Inhibitori kinaza i njihova upotreba u liječenju raka
WO2012000103A1 (en) 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
KR102148355B1 (ko) * 2012-07-27 2020-08-26 사토 파머슈티컬 가부시키가이샤 디플루오로메틸렌 화합물
JP6525983B2 (ja) * 2013-10-18 2019-06-05 ユニバーシティー ヘルス ネットワーク 膵癌の治療法
PT3057965T (pt) 2013-10-18 2019-04-23 Univ Health Network Formas de sal e cristal de inibidor de plk-4
CN104130175A (zh) * 2014-06-13 2014-11-05 天津科技大学 不同位置取代吲哚酮类衍生物及其应用
US11608334B2 (en) 2017-02-08 2023-03-21 The National Institutes of Pharmaceutical R&D Co., Ltd. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
CN108947970B (zh) * 2017-05-18 2022-04-05 四川大学 吲唑类衍生物及其制备方法和用途
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE
EP3959209A4 (en) 2019-04-24 2022-12-28 University Health Network S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE
US20230010772A1 (en) * 2019-12-06 2023-01-12 University Health Network Treatment for acute myeloid leukemia or myelodysplastic syndrome
BR112022022409A2 (pt) 2020-05-06 2023-02-07 Ajax Therapeutics Inc 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
CN112250614B (zh) * 2020-10-20 2022-02-01 苏州大学 3-螺三元环吲哚酮衍生物的合成方法
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202300485A (zh) * 2021-03-02 2023-01-01 大陸商上海齊魯製藥研究中心有限公司 Plk4抑制劑及其用途
CN117794529B (zh) 2021-05-11 2025-02-11 欧瑞克制药公司 Polo样激酶4抑制剂
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
AU2022388555A1 (en) 2021-11-09 2024-05-02 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2024006379A1 (en) * 2022-06-30 2024-01-04 Axonis Therapeutics, Inc. Methods and compounds for inhibiting mkk7 enzymes
TW202448861A (zh) 2023-04-06 2024-12-16 美商輝瑞大藥廠 經取代吲唑丙酸衍生化合物及其用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) * 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ES2251741T3 (es) 1996-08-23 2006-05-01 Sugen, Inc. Bibliotecas combinatorias de indolinona y productos afines y metodos para el tratamiento de enfermedades.
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
WO2000008202A2 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
EP1165513A1 (en) 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
WO2005058309A1 (en) 2003-12-16 2005-06-30 Leo Pharma A/S Novel therapeutic use of indolinone derivatives
US20050211590A1 (en) 2004-03-26 2005-09-29 Mcclure George K Protective cover for medical devices
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7309787B2 (en) * 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2007109026A2 (en) 2006-03-15 2007-09-27 The Trustees Of Columbia University In The City Of New York Pten compositions and methods for detecting breast cancer
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
EP2181108A2 (en) 2007-06-12 2010-05-05 Boehringer Ingelheim International GmbH 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
JP5372939B2 (ja) 2007-09-25 2013-12-18 武田薬品工業株式会社 ポロ様キナーゼ阻害剤
WO2009065232A1 (en) 2007-11-20 2009-05-28 University Health Network Cancer diagnostic and therapeutic methods that target plk4/sak
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
EP2262499B1 (en) * 2008-03-11 2016-12-21 University Health Network Mk-0557 for use in the treatment of cancer
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
WO2010008731A1 (en) 2008-06-16 2010-01-21 Tigris Pharmaceuticals, Inc. Methods for determining sensitivity to aminoflavones
DE102008040187A1 (de) 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
WO2010017047A1 (en) 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Ｊｆｅスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
ME02545B (me) 2010-04-06 2017-02-20 Univ Health Network Inhibitori kinaza i njihova upotreba u liječenju raka
WO2012000103A1 (en) * 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2012121764A1 (en) 2010-11-25 2012-09-13 Ratiopharm Gmbh Novel salts and polymorphic forms of afatinib
EP2681216B1 (en) * 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
EP2766352B1 (en) 2011-10-12 2018-06-06 University Health Network (UHN) Indazole compounds as kinase inhibitors and method of treating cancer with same
JP6525983B2 (ja) 2013-10-18 2019-06-05 ユニバーシティー ヘルス ネットワーク 膵癌の治療法
PT3057965T (pt) 2013-10-18 2019-04-23 Univ Health Network Formas de sal e cristal de inibidor de plk-4

Also Published As

Publication number Publication date
EP2556071A1 (en) 2013-02-13
US20120264800A1 (en) 2012-10-18
WO2011123946A8 (en) 2011-12-08
US10077255B2 (en) 2018-09-18
DK2556071T3 (en) 2016-12-12
AU2011238384A1 (en) 2012-09-27
US20140045838A1 (en) 2014-02-13
LT2556071T (lt) 2017-01-25
US9796703B2 (en) 2017-10-24
US20110263598A1 (en) 2011-10-27
JP5442906B2 (ja) 2014-03-19
US20170226088A1 (en) 2017-08-10
US9579327B2 (en) 2017-02-28
JP2013523784A (ja) 2013-06-17
IL221556A (en) 2015-04-30
CY1118610T1 (el) 2017-07-12
WO2011123947A8 (en) 2011-12-22
US10358436B2 (en) 2019-07-23
SMT201600430B (it) 2017-01-10
TW201134471A (en) 2011-10-16
EP2556071A4 (en) 2013-09-04
PL2556071T3 (pl) 2017-02-28
US20180105511A1 (en) 2018-04-19
KR20130108065A (ko) 2013-10-02
KR101782668B1 (ko) 2017-09-27
CN102892766A (zh) 2013-01-23
US20160045511A1 (en) 2016-02-18
WO2011123946A1 (en) 2011-10-13
US9907800B2 (en) 2018-03-06
TWI516262B (zh) 2016-01-11
CN102892766B (zh) 2015-05-20
SI2556071T1 (sl) 2016-12-30
US8481533B2 (en) 2013-07-09
SG183875A1 (en) 2012-10-30
US20150133677A1 (en) 2015-05-14
BR112012025496A2 (pt) 2020-08-18
ME02545B (me) 2017-02-20
HUE030651T2 (en) 2017-05-29
ES2639757T3 (es) 2017-10-30
MX2012011516A (es) 2013-03-08
US8263596B2 (en) 2012-09-11
EP2556071B1 (en) 2016-08-17
US20180282306A1 (en) 2018-10-04
WO2011123947A1 (en) 2011-10-13
US20130096301A1 (en) 2013-04-18
EP2556070A4 (en) 2013-10-23
AU2011238384B2 (en) 2015-02-19
US9139563B2 (en) 2015-09-22
EP2556070B1 (en) 2017-06-07
HRP20161498T1 (hr) 2016-12-16
EP2556070A1 (en) 2013-02-13
US8921545B2 (en) 2014-12-30
ES2603613T3 (es) 2017-02-28
NZ602350A (en) 2014-05-30
BR112012025496B1 (pt) 2021-02-23
EA023173B1 (ru) 2016-04-29
PT2556071T (pt) 2016-11-22

Similar Documents

Publication Publication Date Title
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
EA201490759A1 (ru) Ингибиторы протеинкиназы
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201690094A1 (ru) Ингибиторы syk
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
EA201690989A1 (ru) Ингибиторы syk
EA201590230A1 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
UA110983C2 (ru) Производная 1,2,3,4-тетрагидрохинолина, пригодная для лечения диабета
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
MX2011009796A (es) Inhibidores de la cinasa pi3.
EA201391568A1 (ru) Новые производные имидазола, подходящие для лечения артрита
TN2014000095A1 (en) Pharmaceutical compositions
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
EA201270373A1 (ru) Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201490919A1 (ru) Производные бетулина
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
EA201491247A1 (ru) Производные дигидробензооксазина и дигидропиридооксазина
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов